{"id":531043,"date":"2021-02-20T18:30:01","date_gmt":"2021-02-20T18:30:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531043"},"modified":"2021-02-20T18:30:01","modified_gmt":"2021-02-20T18:30:01","slug":"intrahepatic-cholangiocarcinoma-icca-market-size-share-competitive-assessment-market-forecast-and-research-report-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/intrahepatic-cholangiocarcinoma-icca-market-size-share-competitive-assessment-market-forecast-and-research-report-2030_531043.html","title":{"rendered":"Intrahepatic Cholangiocarcinoma (ICCA) Market Size, Share, Competitive Assessment, Market Forecast and Research Report 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1613621353.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Intrahepatic Cholangiocarcinoma (ICCA) Market Size, Share, Competitive Assessment, Market Forecast and Research Report 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1613621353.jpeg\" alt=\"Intrahepatic Cholangiocarcinoma (ICCA) Market Size, Share, Competitive Assessment, Market Forecast and Research Report 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u2018Intrahepatic Cholangiocarcinoma (ICCA) &#8211; Market Insights, Epidemiology, and Market Forecast\u20132030\u2019 report deliver an in-depth understanding of the ICCA, historical and forecasted epidemiology as well as the ICCA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsights launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intrahepatic-cholangiocarcinoma-market?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Intrahepatic Cholangiocarcinoma (ICCA) Market Insights, Epidemiology and Market Forecast 2030<\/strong><\/a>.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &lsquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intrahepatic-cholangiocarcinoma-market?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Intrahepatic Cholangiocarcinoma (ICCA) Market Insights, Epidemiology, and Market Forecast&ndash;2030<\/strong><\/a>&rsquo; report deliver an in-depth understanding of the ICCA, historical and forecasted epidemiology as well as the ICCA market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/dfe6f4811d10262aec6e1931b8454601.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Geography Covered:<\/strong>&nbsp;The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan<\/p>\n<p style=\"text-align: justify;\">Intrahepatic cholangiocarcinoma (ICCA), a primary malignant neoplasm of the liver secondary to hepatocellular carcinoma, arises from the intrahepatic biliary epithelium (lining epithelia and peribiliary glands) and shows a variable cholangiocytic differentiation. The malignant tumor may arise from any portion of the bile duct epithelium, i.e., anywhere from the terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural).<\/p>\n<p style=\"text-align: justify;\"><strong>Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology Insights:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In 2017, a total of 10,177 patients were affected with ICCA in the 7MM.<\/li>\n<li>The United States contributes the largest share with 3,639 incident cases in 2017, acquiring about 35.76% of the totals 7MM share. On the other hand, EU5 and Japan will account for 37.40% and 26.84% population share, respectively, by 2017.<\/li>\n<li>ICCA is slightly common in males as compared to females.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Request for sample pages of the report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/intrahepatic-cholangiocarcinoma-market?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/sample-request\/intrahepatic-cholangiocarcinoma-market<\/span><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Intrahepatic Cholangiocarcinoma (ICCA) Emerging Therapies:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Pemazyre (Pemigatinib): Incyte Corporation<\/p>\n<p style=\"text-align: justify;\">2. Rozlytrek (Entrectinib): Roche<\/p>\n<p style=\"text-align: justify;\">3. Melphalan\/HDS: Delcath Systems<\/p>\n<p style=\"text-align: justify;\">4. Derazantinib: Basilea Pharmaceutica<\/p>\n<p style=\"text-align: justify;\"><strong>Intrahepatic Cholangiocarcinoma (ICCA) Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">Intrahepatic cholangiocarcinoma (ICCA) is the type of CCA that forms in the bile ducts inside the liver. The commonly available modalities for the treatment of ICCA include surgery and radiation therapies for curative intent and systemic therapies, including chemotherapy and chemoradiotherapy, for the surgery of ineligible patients.<\/p>\n<p style=\"text-align: justify;\">Surgical resection is the mainstay for the treatment of ICCA. The main goal of the surgery is the hepatic resection with negative margins. Since this type of cancer occurs in the bile ducts inside the liver, surgery may include removing the section or wedge of the liver, and its extent depends on tumor size and location.<\/p>\n<p style=\"text-align: justify;\">Locoregional therapies such as RFA, TACE, DEB-TACE or TACE drug-eluting microspheres, and TARE with yttrium-90 microspheres have shown to be effective in a retrospective analysis of patients with ICCA. Besides these, radiation therapy is also a locoregional treatment option for unresectable ICCA. Fewer patients with ICCA are also given ablation. Although all guidelines recommend radiofrequency ablation (RFA) as a standard treatment for patients with small, early-stage HCC not suitable for surgical therapies, in some cases, patients with ICCA are also treated with RFA.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/intrahepatic-cholangiocarcinoma-market?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Click here and get access to free sample pages of the report.<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Intrahepatic Cholangiocarcinoma (ICCA) Market Insights<br \/><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intrahepatic-cholangiocarcinoma-market?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Intrahepatic Cholangiocarcinoma (ICCA) market size<\/strong><\/a> in the 7MM was USD 99.78 million in 2017.<\/li>\n<li>Among the 7MM, the United States accounts for the highest market size of ICCA in comparison with EU5 and Japan.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1 Key Insight<br \/> 2 Executive Summary of Intrahepatic Cholangiocarcinoma (ICCA)<br \/> 3 Intrahepatic Cholangiocarcinoma (ICCA) Market Overview at a Glance<br \/> 4 Disease Background and Overview: Intrahepatic Cholangiocarcinoma (ICCA)<br \/> 5 Case Reports<br \/> 6 Intrahepatic Cholangiocarcinoma (ICCA) Epidemiology and Patient Population<br \/> 7 United States Epidemiology<br \/> 8 EU5 Epidemiology<br \/> 9 Japan Epidemiology<br \/> 10 Current Intrahepatic Cholangiocarcinoma (ICCA) Treatment and Medical Practices<br \/> 11 Unmet needs<br \/> 12 Intrahepatic Cholangiocarcinoma (ICCA) Marketed Drugs<br \/> 13 Intrahepatic Cholangiocarcinoma (ICCA) Emerging Drugs<br \/> 14 Intrahepatic Cholangiocarcinoma (ICCA) 7MM Market Analysis<br \/> 15 United States<br \/> 16 EU-5 countries: Market Outlook<br \/> 17 Japan Market Outlook<br \/> 18 Intrahepatic Cholangiocarcinoma (ICCA) Market Drivers<br \/> 19 Intrahepatic Cholangiocarcinoma (ICCA) Market Barriers<br \/> 20 SWOT Analysis<br \/> 21 Reimbursement and market access<br \/> 22 Appendix<br \/> 23 DelveInsight Capabilities<br \/> 24 Disclaimer<br \/> 25 About DelveInsight<\/p>\n<p><strong> About DelveInsight<\/strong><br \/><strong> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=intrahepatic-cholangiocarcinoma-icca-market-size-share-competitive-assessment-market-forecast-and-research-report-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=intrahepatic-cholangiocarcinoma-icca-market-size-share-competitive-assessment-market-forecast-and-research-report-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u2018Intrahepatic Cholangiocarcinoma (ICCA) &#8211; Market Insights, Epidemiology, and Market Forecast\u20132030\u2019 report deliver an in-depth understanding of the ICCA, historical and forecasted epidemiology as well as the ICCA market trends in the United States, EU5 (Germany, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/intrahepatic-cholangiocarcinoma-icca-market-size-share-competitive-assessment-market-forecast-and-research-report-2030_531043.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-531043","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531043"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531043\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}